Virax Net Debt To E B I T D A from 2010 to 2024
| VRAX Stock | USD 1.95 0.02 1.02% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.50913462 | Current Value 0.48 | Quarterly Volatility 8.72158581 |
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 97.9 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 8.96, Dividend Yield of 0.0 or PTB Ratio of 0.29. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
Virax | Net Debt To E B I T D A |
Latest Virax Biolabs' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Virax Biolabs Group over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Virax Biolabs' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Virax Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 2.62 | |
| Geometric Mean | 1.57 | |
| Coefficient Of Variation | 332.72 | |
| Mean Deviation | 5.70 | |
| Median | (1.14) | |
| Standard Deviation | 8.72 | |
| Sample Variance | 76.07 | |
| Range | 25.133 | |
| R-Value | 0.39 | |
| Mean Square Error | 69.66 | |
| R-Squared | 0.15 | |
| Significance | 0.15 | |
| Slope | 0.75 | |
| Total Sum of Squares | 1,065 |
Virax Net Debt To E B I T D A History
About Virax Biolabs Financial Statements
Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.51 | 0.48 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.